

FORM210

FSGS Novel Therapies (FONT-II)

Screening Form (Form # 210)

Prior to each individual participant's shipment (blood and/or urine) to Spectra, a hard copy of page 1 of this Form 10 **must** be included inside the shipping container. This step is for each first shipment (per participant) to Spectra. Also, this form should be entered within 24-hours into the Oracle database.

--	--	--	--	--	--

1. Participant ID number
PID

--	--

2. Alpha code
ALPHCD

B	0	1
----------	----------	----------

3. Visit Number
CPEVENT / VISIT_NUMBER /
SUBEVENT_NUMBER

- 4. a. Was this participant enrolled in the FSGS-CT Study? (0=no, 1=yes) ___ FSGSCT
- b. If Q4a is yes, FSGS-CT PID Number..... ___ ___ ___ ___ FSGSID
- 5. Date of birth (dd/mmm/yyyy) ___ ___ / ___ ___ ___ / ___ ___ ___ DOB
- 6. Gender (1=male, 2=female) ___ SEX
- 7. a. Ethnicity ETHNIC
 1 = Not Hispanic or Latino, 2 = Hispanic or Latino, 8 = Unknown/Not reported
- b. Race RACE
 1 = American Indian/Alaska Native 2 = Asian
 3 = Black or African American 4 = White
 5 = More than one race 8 = Unknown/Not reported

Inclusion Criteria – all must be completed

- 8. FSGS confirmed by renal biopsy? BIOPSY
 1 = FONT pathologist confirmed, 2 = FSGS-CT pathologist confirmed, 3 = not confirmed, pending
- 9. Age at onset of proteinuria Years ___ AGEONS Months ___ MONONS
- 10. Locally estimated GFR (ml/min/1.73 m²) ___ GFR
 [Estimated GFR using Schwartz (age <18 yr) or Cockcroft-Gault (age ≥ 18 yr)]
- 11. Local Up/c > 1.0 g/g creatinine on first morning void? (0=no, 1=yes) ___ UPCGTI
- 12. Practicing acceptable forms of birth control (female) BIRCON
 1 = pre pubertal, post menopausal or surgically sterile 4 = none of the above
 2 = abstinent 8 = not applicable (male)
 3 = agrees to use two forms of birth control
- 13. Blood pressure is controlled <140/90 (≥ 18 yrs) or <95th percentile

FAX COMPLETED FORM TO FONT STUDY DESK
UMich (734) 232-2353 NYU (212) 263-4053

for age and height (< 18 yrs)..... (0=no, 1=yes)___CTRLBP

14. Resistant to prior prescribed immunomodulatory therapy (0=no, 1=yes)___RESIMM

Exclusion Criteria – all must be completed

15. Is the patient currently pregnant or breastfeeding?..... (0=no, 1=yes, 8=Male, N/A)___PREGBF

16. Ever diagnosed with or received: (0=no, 1=yes)

a. Transplant organ or bone marrow? __RCVTX

b. Malignancy (history of)? __DXMLG

c. Diabetes Mellitus? __DXDM

d. Hepatic Disease, Cirrhosis, Hepatitis, or chronic active liver disease?..... __DXHEP

e. HIV or AIDS? __DXHIV

f. Other active serious infection? __DXINF

g. Congestive Heart Failure? __DXCHF

h. Myocardial Infarction (history of)? __DXMYOC

i. Multiple Sclerosis? __DXMS

j. Systemic Lupus Erythematosus? __DXSLE

17. Participation in another therapeutic trial involving protocol mandated Administration of a immunosuppressive medication concurrently or 30 days prior to randomization? (0=no, 1=yes)___OTHTRL

18. Has the participant ever been treated with the following agents:

a. Adalimumab or other TNF α antagonist?..... (0=no, 1=yes)___TNFA

b. Galactose.....(0=no, 1=yes)___GALACT

19. Has participant received any immunosuppressive agents other than steroids in the past 30 days?(0=no, 1=yes)___IMMRX

20. Has participant received Rituximab in the past 90 days?(0=no, 1=yes)___RITUX

Medical History

21. Has the patient ever been treated with:
[0=no, 1=yes, 9=unknown (a-j), enter UNK= unknown (a1 – j1)]

a. Cyclosporine? __CSA

1. Estimated cumulative exposure (in months)..... __ __ __CSAMON

b. Tacrolimus? __TACROL

1. Estimated cumulative exposure (in months)..... __ __ __TACMON

c. Azathioprine?..... __AZATHI

1. Estimated cumulative exposure (in months)..... __ __ __AZAMON

d. Mycophenolate?..... __MMF

- 1. Estimated cumulative exposure (in months)..... ___ ___ ___MMFMON
- e. Sirolimus?.....___SIROL
 - 1. Estimated cumulative exposure (in months)..... ___ ___ ___SIRMON
- f. Rituximab?.....___RTX
 - 1. Estimated cumulative exposure (in months)..... ___ ___ ___RTXMON
- g. Steroids?___STROID
 - 1. Estimated cumulative exposure (in months)..... ___ ___ ___STRMON
- h. Cyclophosphamide?.....___CYTXN
 - 1. Estimated cumulative exposure (in months)..... ___ ___ ___CYTMON
- i. Chlorambucil?.....___CHLORM
 - 1. Estimated cumulative exposure (in months)..... ___ ___ ___CHLMON
- j. Other immunosuppressives.....___IMMSUP
 - 1. Estimated cumulative exposure (in months)..... ___ ___ ___IMMMON

22. Current and chronic health conditions in the past 5 years for which medical care was received?

Condition:	MedDRA Code:
a. MDVT	MDCLLT
b.	
c.	
d.	

Does the participant meet the criteria of:

- 23. a. Steroid resistance (failure to achieve sustained Up/c <1.0 following a standard course of prednisone/prednisolone/methylprednisolone prescribed for FSGS therapy___STRRES
 - 1 = steroid resistant
 - 2 = established intolerance to steroids
 - 3 = anticipated intolerance to steroids
 - 4 = none of the above (not eligible)
 - b. Patient immunosuppressive status:___IMSTAT
 - 1 = off all immunosuppressives including steroids
 - 2 = on minimal dose of corticosteroids for stability/discussed with Drs. Trachtman or Gipson
 - 3 = on minimal dose of corticosteroids for stability/not yet discussed with Drs. Trachtman or Gipson
 - 4 = currently using more than a minimal dose of immunosuppressives (including steroids)
24. a. Is the participant taking ACEi/ARB therapy? (0=no; 1=ACEi only; 2=ARB only; 3=both)
___ACEARB1
- b. In the judgment of the site PI, has participant been on a full and steady dose of ACEi and/or ARB for at least 2 weeks, at the time of B01 visit?

(0 = no, 1 = yes, 2 = yes, but on ACEi only, 3 = yes, but on ARB only, 8 = not applicable) ___ACEARB2

25. Has ACEi or ARB ever been stopped due to intolerance? (0=no; 1=ACEi; 2=ARB; 3=both)
___OFFAA

26. Does the participant have a known allergy to:

- a. Angiotensin Converting Enzyme Inhibitors (ACEi)?..... (0=no 1=yes)___ALGACE
- b. Angiotensin Receptor Blockers (ARB)? (0=no 1=yes)___ALGARB
- c. Atorvastatin (Lipitor)..... (0=no 1=yes)___ALGLIP
- d. Adalimumab?.....(0=no 1=yes)___ALGADA

27. Past Medical History:

- a. Birth weight of participant (enter UNK = unknown).....(kg)___ ____.___BIRTHWT
- b. Was the participant born prematurely? (0=no, 1=yes, 9=unknown)___PRBORN
- c. If yes, how many weeks prematurely
(enter UNK = unknown, NA = not applicable)..... (wks)___ __PBWKS

Have participant ever had:

- 28. Seizures?(0=no 1=yes)___SEIZUR
- 29. Blood clot?.....(0=no 1=yes)___BDCLOT
- 30. Hypertension?(0=no 1=yes)___HIGHBP

Heart Condition:

- 31. a. Arrhythmia?.....(0=no 1=yes)___ARRHY
- b. LVH?(0=no 1=yes)___LVH
- c. Congenital deformality? (0=no 1=yes)___DEFM
- d. Valvular disease?.....(0=no 1=yes)___VALVDS
- e. Other condition?(0=no 1=yes)___OTHCON

1. If Other, specify:

Condition:	MedDRA Code:
MDVT	MDCLLT

- 32. a. Smoking History(0=never, 1=former smoker, 2=current smoker, 9=unknown)___
SMOKE
- b. If current smoker, estimate number of cigarettes per day (NA=not applicable)___ __
SMKNUM

- 201. a. Principal Investigator (PI) Signature ... _____
Q201a is not entered into database
- b. F210 signed by PI (0=no, 1=yes) ___ PISIGN
- c. "Username" of PI..... _____
- d. Date form signed by PI.....(dd/mmm/yyyy) ____ / ____ / ____ PIDT